Cancer Gene Therapy Market Size & Growth Forecast 2027–2036, By Segments (Product Therapy, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Cancer Gene Therapy Market size was valued at USD 6.2 billion in 2026 and is anticipated to grow at a 18.34% CAGR from 2027 to 2036, exceeding USD 33.4 billion by 2036. The industry revenue for 2027 is calculated at USD 7.16 billion.
Get more details on this report
Request Free Sample ReportCancer Gene Therapy Market Intelligence Snapshot
Regional Market Dynamics
- North America holds 63.92% share, supported by advanced oncology centers, strong biopharmaceutical ecosystem, and high clinical trial activity enabling faster therapy adoption.
- Europe is expanding at 21.17% CAGR, driven by translational research networks, rising multicenter trials, and broader integration of gene therapies into oncology care.
Segment Momentum
- Oncolytic virotherapy held a 55.99% share in 2026, supported by its established tumor-targeting approach and strong alignment with ongoing oncology development and clinical research programs.
- Biopharmaceutical companies are growing fastest as commercialization advances, leveraging their capabilities in manufacturing, regulatory execution, and clinical development to transform promising research into product-focused programs.
Market Expansion Drivers
- Rising global cancer incidence increasing demand for targeted gene-based therapeutic interventions.
- Advancements in gene editing and cell engineering improving clinical efficacy of oncology therapies.
- Expanding biopharmaceutical collaborations accelerating commercialization of personalized cancer gene therapies.
Leading Market Participants
- Leading players in the cancer gene therapy market include Amgen Inc. (United States), Novartis AG (Switzerland), Gilead Sciences, Inc. (United States), bluebird bio, Inc. (United States), Bristol-Myers Squibb Company (United States), Legend Biotech Corporation (United States), JW Therapeutics (China), CARsgen Therapeutics (China), Nanjing IASO Biotechnology Co., Ltd. (China), Krystal Biotech, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 6.2 billion
- 2027 Estimated Market Size: USD 7.16 billion.
- Projected Market Size: USD 33.4 billion by 2036
- Growth Forecast: 18.34% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Europe
- Core Revenue Segment: Oncolytic Virotherapy (Product Therapy) | Research Institutes (End Use)
- Emerging Opportunity Segment: Gene Induced Immunotherapy (Product Therapy) | Biopharmaceutical Companies (End Use)
Market Growth Drivers and Industry Trends
Rising global cancer incidence increasing demand for targeted gene-based therapeutic interventions
The increasing global burden of cancer is strengthening the need for therapies that can address disease at the genetic level, particularly where conventional treatment approaches may have limitations. The cancer gene therapy market is benefiting from greater demand for targeted interventions designed to modify, replace, or regulate genes associated with tumor development, enabling more disease-specific therapeutic strategies. As oncology care increasingly emphasizes precision treatment, gene-based approaches are gaining relevance for patients requiring therapies tailored to specific cancer characteristics.
Advancements in gene editing and cell engineering improving clinical efficacy of oncology therapies
Technological progress in gene editing and cell engineering is enhancing the ability to develop more precise and effective oncology treatments. These advances are supporting the cancer gene therapy market by improving the design and functional performance of therapeutic cells and genetic interventions, while enabling researchers to address specific molecular drivers of cancer. Greater control over genetic modification and cellular behavior is also expanding the development potential of therapies intended to deliver more targeted treatment responses.
Expanding biopharmaceutical collaborations accelerating commercialization of personalized cancer gene therapies
Strategic collaboration across the biopharmaceutical ecosystem is helping translate personalized gene therapy research into commercially viable oncology treatments. The cancer gene therapy market is gaining momentum as partnerships combine specialized capabilities in genetic technologies, clinical development, manufacturing, and therapeutic delivery, helping address the complexity of bringing individualized treatments through development. Such collaborations can also support the scaling of specialized production and broaden access to emerging personalized cancer therapies.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global cancer incidence increasing demand for targeted gene-based therapeutic interventions | 2.40% | High | North America, Europe, Asia Pacific | High | Near Term |
| Advancements in gene editing and cell engineering improving clinical efficacy of oncology therapies | 2.10% | High | North America, Europe | High | Mid Term |
| Expanding biopharmaceutical collaborations accelerating commercialization of personalized cancer gene therapies | 1.80% | High | North America, Asia Pacific | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America led the cancer gene therapy market, accounting for a 63.92% share in 2026, supported by advanced biomedical research capabilities, strong clinical development infrastructure, and substantial investment in innovative oncology treatments. The region benefits from a well-established ecosystem for gene therapy research, including specialized healthcare institutions, sophisticated laboratory infrastructure, and growing access to precision medicine. Increasing adoption of personalized cancer treatments is also encouraging demand for gene-based therapeutic approaches, particularly as researchers and healthcare providers focus on treatments designed around specific molecular characteristics of tumors. Supportive regulatory pathways, established healthcare systems, and continued investment in cell and gene therapy manufacturing further strengthen North America's position in the market.
Europe (Fastest-Growing Region)
Europe is the fastest-growing region, driven by increasing emphasis on precision oncology, expanding clinical research activity, and rising investment in advanced therapeutic technologies. Growing awareness of personalized cancer treatment and improvements in molecular diagnostics are creating a stronger foundation for gene therapy development and adoption. The region's efforts to strengthen biotechnology research, improve access to innovative medicines, and expand specialized treatment infrastructure are also supporting market expansion. In addition, collaboration between research institutions, healthcare providers, and biotechnology organizations is contributing to the development and clinical translation of emerging gene-based cancer therapies.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Translational Research NetworkGermany advances cancer gene therapy through strong collaboration between academic institutions, hospitals, and biotechnology companies. Clinical programs in Germany increasingly emphasize scalable manufacturing and robust evidence generation for innovative therapeutic approaches.
France 🇫🇷
Collaborative Oncology ProgramsFrance supports cancer gene therapy through coordinated research initiatives and specialized oncology treatment networks. Healthcare institutions in France continue emphasizing clinical collaboration and regulatory alignment to facilitate responsible therapeutic adoption.
Italy 🇮🇹
Academic Clinical PartnershipsItaly strengthens the cancer gene therapy market through partnerships linking research institutions with specialized oncology centers. Clinical teams in Italy increasingly focus on integrating innovative therapies into established cancer care pathways while expanding translational expertise.
Japan 🇯🇵
Precision Therapy DevelopmentJapan focuses on cancer gene therapy platforms that complement precision medicine and personalized oncology strategies. Research organizations in Japan continue strengthening translational capabilities while supporting carefully evaluated clinical implementation.
South Korea 🇰🇷
Biotech Commercialization MomentumSouth Korea expands cancer gene therapy capabilities through growing biotechnology investment and advanced cell and gene therapy infrastructure. Companies in South Korea increasingly pursue collaborative development models that accelerate clinical progress and manufacturing readiness.
United States 🇺🇸
Clinical Translation EcosystemThe U.S. cancer gene therapy market benefits from active clinical development, biotechnology innovation, and specialized treatment centers. Organizations across the U.S. continue advancing manufacturing capabilities and collaborative research to expand access to next-generation therapies.
Segment Leadership and Growth Trends
Cancer Gene Therapy Market Share (%), by Product Therapy, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Therapy Segment Analysis: Oncolytic Virotherapy (Largest Segment) vs Gene Induced Immunotherapy (Fastest-Growing Segment)
Oncolytic virotherapy held the largest share of the cancer gene therapy market, accounting for 55.99% in 2026. Its leading position is supported by the therapeutic potential of engineered viruses to selectively target cancer cells while stimulating immune responses against tumors. This approach combines direct tumor cell destruction with broader immune activation, making it an important area of investigation within precision oncology. Increasing research into tumor-specific viral mechanisms, improvements in viral engineering, and the growing need for therapies that can address difficult-to-treat cancers are supporting continued adoption of oncolytic virotherapy.
Gene induced immunotherapy is expected to be the fastest-growing product therapy segment, driven by increasing efforts to use genetic modification to enhance the body's immune response against cancer. Advances in immune-cell engineering and gene-based treatment strategies are expanding opportunities to develop more targeted approaches to tumor recognition and elimination. Growing interest in personalized cancer therapies and the need to overcome immune evasion and treatment resistance are further encouraging investment and research in gene-induced immune interventions.
End Use Segment Analysis: Research Institutes (Largest Segment) vs Biopharmaceutical Companies (Fastest-Growing Segment)
Research institutes led the end-use segment of the cancer gene therapy market, accounting for a 55.99% share in 2026. Their dominant role reflects the importance of fundamental and translational research in understanding gene-based mechanisms, identifying therapeutic targets, and evaluating the safety and efficacy of emerging cancer therapies. Research institutions provide the specialized laboratory capabilities needed for vector development, genetic engineering, preclinical experimentation, and evaluation of novel treatment approaches. Continued scientific interest in precision medicine and advanced cancer biology is sustaining strong demand from this end-user group.
Biopharmaceutical companies are expected to be the fastest-growing end-use segment as the development of gene-based oncology treatments increasingly moves from laboratory research toward therapeutic development and commercialization. These organizations are expanding capabilities in gene delivery, cell engineering, clinical development, and manufacturing to advance innovative cancer treatments. Increasing collaboration between research and industry environments, alongside growing interest in personalized oncology and next-generation therapeutic platforms, is strengthening the role of biopharmaceutical companies in the market.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product Therapy | Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer | Oncolytic Virotherapy | Gene Induced Immunotherapy |
| End Use | Research Institutes, Biopharmaceutical Companies, Diagnostic Centers, Others | Research Institutes | Biopharmaceutical Companies |
Competitive Landscape and Market Positioning
Key companies in the cancer gene therapy market:
1. Amgen Inc. (United States)
2. Novartis AG (Switzerland)
3. Gilead Sciences Inc. (United States)
4. bluebird bio Inc. (United States)
5. Bristol-Myers Squibb Company (United States)
6. Legend Biotech Corporation (United States)
7. JW Therapeutics (China)
8. CARsgen Therapeutics (China)
9. Nanjing IASO Biotechnology Co. Ltd. (China)
10. Krystal Biotech Inc. (United States)
The cancer gene therapy market is advancing rapidly with innovative genetic modification approaches aimed at improving targeted cancer treatment outcomes. Continuous research in gene delivery systems is enhancing therapeutic precision and effectiveness. The cancer gene therapy market is increasingly shaped by next-generation oncology treatment breakthroughs.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Amgen Inc. (United States) | |||||||
| Novartis AG (Switzerland) | |||||||
| Gilead Sciences Inc. (United States) | |||||||
| bluebird bio Inc. (United States) | |||||||
| Bristol-Myers Squibb Company (United States) | |||||||
| Legend Biotech Corporation (United States) | |||||||
| JW Therapeutics (China) | |||||||
| CARsgen Therapeutics (China) | |||||||
| Nanjing IASO Biotechnology Co. Ltd. (China) | |||||||
| Krystal Biotech Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Rznomics | May-26 | Rznomics received FDA RMAT designation for its lead investigational gene therapy, RZ-001, for hepatocellular carcinoma. This regulatory milestone facilitates expedited development and intensified engagement with the FDA, underscoring the candidate’s clinical potential and strengthening the company's competitive position within the oncology RNA-based gene therapy landscape. |
| Kolon Life Science | Feb-26 | Kolon Life Science is undergoing a significant leadership transition following the departure of its CEO amid a strategic pivot in its gene therapy pipeline. While the company continues to focus on advancing new drug candidates in the oncology sector, this management change introduces operational uncertainty regarding the long-term execution of its clinical development and business performance objectives. |
| Rznomics | Dec-25 | Rznomics’ RZ-001 candidate was designated an “outstanding project” by the Korea Drug Development Fund. This institutional support and validation from the National New Drug Development Program bolster the company's development trajectory for glioblastoma and hepatocellular carcinoma, providing critical resources to advance its first-in-class RNA-based platform toward clinical and commercial readiness. |
| viTToria Biotherapeutics | Dec-25 | viTToria Biotherapeutics was honored with the Startup of the Year Award by the Penn Center for Innovation. This recognition highlights the company's notable progress in developing innovative T-cell lymphoma therapies, signaling growing market interest and technical advancement in next-generation immunotherapeutic approaches for hematologic malignancies. |
| N/A | Dec-25 | A base-edited CAR T-cell therapy achieved a life-saving outcome in a teenager with acute T-cell leukemia. This breakthrough demonstrates the increasing clinical feasibility and transformative potential of gene-editing technologies in treating aggressive, refractory blood cancers, effectively expanding the addressable patient population for next-generation engineered cell therapy platforms. |
| Ferring Pharmaceuticals | Oct-24 | Ferring Pharmaceuticals expanded its global manufacturing capacity for the gene therapy Adstiladrin by inaugurating a production hub in Finland and partnering with CDMO SK pharmteco. This strategic expansion of the supply chain is designed to address the accelerating clinical and commercial demand for its bladder cancer therapy, enhancing operational resilience and distribution scale. |
| ImmunoACT | Apr-24 | ImmunoACT launched India’s first indigenous CAR T-cell therapy, a significant milestone in enhancing the accessibility of advanced oncology immunotherapy. Developed in collaboration with the Indian Institute of Technology Bombay and the Tata Memorial Centre, this localized manufacturing and commercialization effort introduces a more cost-effective alternative to international products, altering the competitive landscape for hematologic cancer treatment in the region. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Cancer Gene Therapy Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Cancer Type | Blood Cancers, Solid Tumors, Central Nervous System Cancers, Other Cancers |
| Gene Delivery Vector | Viral Vectors, Non-Viral Vectors |
| Administration Route | Intravenous, Intratumoral, Intraperitoneal, Other Routes |
Cancer Gene Therapy Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Gene Therapy Clinical Adoption Assessment |
|
| Treatment Pipeline Opportunity Analysis |
|
| Healthcare Reimbursement and Access Landscape |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the cancer gene therapy market?
How much is the cancer gene therapy industry expected to grow by 2036?
How are advances in gene engineering accelerating commercialization in the cancer gene therapy market?
Why are biopharmaceutical collaborations becoming critical to cancer gene therapy market expansion?
Why is oncolytic virotherapy the leading product therapy in the cancer gene therapy market?
Why are biopharmaceutical companies the fastest-growing end users in the cancer gene therapy market?
Why does North America lead the cancer gene therapy market?
Why is Europe the fastest-growing region in cancer gene therapy?
Who are the leading players in the cancer gene therapy landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization